Evidence network for deaths_(OS)

4NCI E3805 (Scott), 2017 STAMPEDE docetaxel, 2016 CHAARTED, 0 GETUG-AFU 15, 20132ARASENS , 2022 PEACE-1, 20225LATITUDE, 2019 TITAN, 2019 ENZAMET, 2019 STAMPEDE abiraterone, 2017 ARCHES, 20222CA184-095, 2017 CA184-043, 2014placebodocetaxel plus ADTandrogen deprivation therapy (ADT)ipilimumab alonepembrolizumab based treatmentdarolutamide plus doxetaxel plus ADTabiraterone plus ADTenzalutamide plus ADTabiraterone plus docetaxel plus ADTapalutamide plus ADTdirect evidencenetwork meta-analysis
T vs. C placebodocetaxel plus ADTandrogen deprivation therapy (ADT)ipilimumab alonepembrolizumab based treatmentdarolutamide plus doxetaxel plus ADTabiraterone plus ADTenzalutamide plus ADTabiraterone plus docetaxel plus ADTapalutamide plus ADT
placebo---NANANANANANANANANA
docetaxel plus ADTNA---NANANANANANANANA
androgen deprivation therapy (ADT)NANA---NANANANANANANA
ipilimumab aloneNANANA---NANANANANANA
pembrolizumab based treatmentNANANANA---NANANANANA
darolutamide plus doxetaxel plus ADTNANANANANA---NANANANA
abiraterone plus ADTNANANANANANA---NANANA
enzalutamide plus ADTNANANANANANANA---NANA
abiraterone plus docetaxel plus ADTNANANANANANANANA---NA
apalutamide plus ADTNANANANANANANANANA---

pathologies: 12,206,207,208,332 - treatments: 1352 result logic